Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CIT | O14578 | 6/20 | 0.49 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 3/20 | 0.44 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | AKT2 | P31751 | 2/20 | 0.42 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620688 | 1.00 | CIT (0.49) | CITWNT3AAKT1ENPP3ENPP1 | |
| Hydrochloric Acid SCHEMBL540138 | 0.99 | CIT (0.48) | CITWNT3AAKT1ENPP3ENPP1 | |
| SCHEMBL25358968 | 0.85 | SLC7A5 (0.53) | CITAKT1AKT2AKT3NPC1 | |
| SCHEMBL25358973 | 0.85 | SLC7A5 (0.53) | CITAKT1AKT2AKT3NPC1 | |
| Hydrochloric Acid SCHEMBL27850092 | 0.81 | NPC1 (0.41) | WNT3AAKT1AKT2AKT3NPC1 | |
| SCHEMBL6495560 | 0.81 | LOXL2 (0.47) | AKT1MAPT | |
| Hydrochloric Acid SCHEMBL6495555 | 0.80 | LOXL2 (0.46) | AKT1MAPT | |
| Hydrochloric Acid SCHEMBL6495563 | 0.80 | LOXL2 (0.46) | AKT1MAPT | |
| SCHEMBL3629762 | 0.80 | CIT (0.45) | CIT | |
| SCHEMBL30167503 | 0.80 | CIT (0.45) | CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175003-B2 | Substituted azoanthracene derivatives and intermediates for preparation thereof | VTV THERAPEUTICS LLC (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2413693-B1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | VTV THERAPEUTICS LLC | 2015-05-28 | — | — | US | disclosed |
| US-8987295-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8383644-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| WO-2010114824-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TRANSTECH PHARMA INC (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLP1R, GIPR, GPR119 | CIT 2336/4885WNT3A 2228/4885AKT1 2543/4885 |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | GLP1R, GIPR, GPR119 | CIT 2873/4885WNT3A 1626/4885AKT1 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.